Which adverse effect is observed with evinacumab?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Evinacumab, as a monoclonal antibody given by IV infusion, carries a risk of hypersensitivity reactions. While milder and more common adverse events like nasopharyngitis or back pain can occur, the safety profile includes the potential for severe hypersensitivity reactions, including anaphylaxis. This is why monitoring during and after the infusion is essential and why clinicians keep emergency measures ready. The key point is that, unlike some more common, mild symptoms, the possibility of a serious hypersensitivity reaction is a recognized and important safety concern with this therapy.